The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study

Autor: Waldherr, C. *, Pless, M., Maecke, H.R., Haldemann, A., Mueller-Brand, J.
Zdroj: In Annals of Oncology July 2001 12(7):941-945
Databáze: ScienceDirect